B

Bioventus Inc
NASDAQ:BVS

Watchlist Manager
Bioventus Inc
NASDAQ:BVS
Watchlist
Price: 9.58 USD 0.31%
Market Cap: 777.4m USD
Have any thoughts about
Bioventus Inc?
Write Note

Bioventus Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bioventus Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
B
Bioventus Inc
NASDAQ:BVS
Total Liabilities & Equity
$810.9m
CAGR 3-Years
18%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Haemonetics Corp
NYSE:HAE
Total Liabilities & Equity
$2.5B
CAGR 3-Years
12%
CAGR 5-Years
16%
CAGR 10-Years
6%
ICU Medical Inc
NASDAQ:ICUI
Total Liabilities & Equity
$4.3B
CAGR 3-Years
33%
CAGR 5-Years
21%
CAGR 10-Years
23%
Align Technology Inc
NASDAQ:ALGN
Total Liabilities & Equity
$6.4B
CAGR 3-Years
4%
CAGR 5-Years
22%
CAGR 10-Years
21%
Lantheus Holdings Inc
NASDAQ:LNTH
Total Liabilities & Equity
$2B
CAGR 3-Years
34%
CAGR 5-Years
38%
CAGR 10-Years
23%
Merit Medical Systems Inc
NASDAQ:MMSI
Total Liabilities & Equity
$2.4B
CAGR 3-Years
13%
CAGR 5-Years
6%
CAGR 10-Years
12%
No Stocks Found

Bioventus Inc
Glance View

Market Cap
777.2m USD
Industry
Health Care

Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.

BVS Intrinsic Value
11.53 USD
Undervaluation 17%
Intrinsic Value
Price
B

See Also

What is Bioventus Inc's Total Liabilities & Equity?
Total Liabilities & Equity
810.9m USD

Based on the financial report for Dec 31, 2023, Bioventus Inc's Total Liabilities & Equity amounts to 810.9m USD.

What is Bioventus Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
13%

Over the last year, the Total Liabilities & Equity growth was -41%. The average annual Total Liabilities & Equity growth rates for Bioventus Inc have been 18% over the past three years , 13% over the past five years .

Back to Top